Home Page Register login

WCIRDC Program Objectives

The program is designed to evaluate both clinical and basic science aspects of diabetes, obesity, and CVD, focusing on insulin resistance, hyperinsulinemia, fat cell, incretins, the gut, the brain, the kidney and energy metabolism.  The goal is to understand pathophysiology, and to develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:

  • State the role of obesity in the development of cardiometabolic diseases, and its management based on a complications-centric model.
  • Explain the roles of diabetes and insulin resistance in the development of kidney disease, retinopathy, and CVD.
  • State how CHF as a consequence of diabetes, insulin resistance, and obesity, and understand contemporary management.
  • Evaluate the extent of PVD and PAD in diabetes and obesity, and know their prevention and management modalities.
  • Explain the role of the kidney in energy metabolism, in diabetes, and in the development of CVD.
  • Discuss the role of the brain in energy balance and obesity.
  • Expalin hypercoagulation and thrombosis as consequences of insulin resistance, inflammation, and diabetes; and be aware of therapeutic agents.
  • Discuss roles of inflammation and immunity in the effect of fat cells on the development of cardiometabolic conditions.
  • Describe how to manage insulin resistance in diabetes with lifestyle, oral medications, and insulin.
  • Explain the role of lipids, in particular low-density lipoproteins (LDL), in the development of atherosclerosis; and the role of medical societies’ guidelines in directing management.
  • Discuss the role of incretins, in particular glucagon-like peptide-1 (GLP-1), in the management of obesity & diabetes and their complications.
  • Describe the use of sodium-glucose linked transporter 2 inhibitors (SGLT-2i) in the management of diabetes, and recognize their role in metabolism.
  • Explain obesity’s relation to food addiction, the role of taste receptors, hormonal response, and dopaminergic receptors.
  • Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia.
  • Describe polycystic ovary syndrome (PCOS) as a cardiometabolic condition.
  • State the pathophysiology and complications of fatty liver disease.
  • Evaluate the benefits and safety of anti-diabetic and obesity medications.
   © WCIR.org